Zafgen today announced that the Company received a letter last week from the U.S. Food and Drug Administration (FDA) placing a clinical hold on the Investigational New Drug Application (IND) for its first U.S. clinical trial of ZGN-1061, the Company’s se http://globenewswire.com/news-release/2018/11/26/1656466/0/en/Zafgen-Provides-Update-on-Investigational-New-Drug-Application-for-ZGN-1061.html

Valeritas Holdings, Inc. today announced the publication of a manuscript titled “Evaluation of a Weekly Physician-Driven Bolus Titration Algorithm in Patients with Type 2 Diabetes Prescribed V-Go® Wearable Insulin Delivery Device for Basal-Bolus Therapy, https://www.apnews.com/0811304073a957f8940bcac06cc5dfb2

Long-term canagliflozin use was associated with reduced body weight and a dose-dependent reduction in BP compared with placebo among patients with type 2 diabetes, according to findings presented at the American Heart Association Scientific Sessions. To https://www.healio.com/cardiology/diabetes/news/online/%7B59375aed-a727-4c8a-ab54-b7b6ef90777e%7D/invokana-maintains-reduction-in-weight-loss-bp-at-1-year

Recent studies have shown that sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists significantly improve CV outcomes, according to an American College of Cardiology expert consensus decision pathway published in the Jo https://www.healio.com/cardiology/chd-prevention/news/online/%7B34f9e872-4842-4d5a-bfe9-fcdb050a5410%7D/acc-sglt2-inhibitors-glp-1-agonists-reduce-cv-risk-in-type-2-diabetes

A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends Jardiance® (empagliflozin) as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with type 2 di https://www.prnewswire.com/news-releases/jardiance-recommended-as-preferred-sglt2-inhibitor-for-adults-with-type-2-diabetes-and-established-cardiovascular-disease-in-american-college-of-cardiology-expert-consensus-decision-pathway-300755291.html